This new text is the only available reference to assemble, review, and synthesize the latest studies on translational therapies and discuss the impact of molecular pathogenesis, biology, and prognostic factors on the diagnosis, prognosis, individualization of treatment, and treatment development for patients with myeloma.

This source discusses:

• therapeutic strategies for clinicians and researchers
• agents that target both the tumor cell and its bone marrow microenvironment
• bone marrow microenvironment in the regulation of growth, survival, and homing of multiple myeloma
• therapies in phase I and phase II trials and therapeutic options for patients with newly diagnosed or relapsed/refractory multiple myeloma
• therapies for other plasma cell disorders and next generation agents and combination therapies
• translational work in multiple myeloma, from advances in molecular pathogenesis to prognostic factors and immunotherapy